Author/Authors :
Noci، نويسنده , , Ivo and Coronnello، نويسنده , , Marcella and Borri، نويسنده , , Patrizia and Borrani، نويسنده , , Elena and Giachi، نويسنده , , Massimo and Chieffi، نويسنده , , Orlando and Marchionni، نويسنده , , Mauro and Paglierani، نويسنده , , Milena and Buccoliero، نويسنده , , Anna Maria and Cherubini، نويسنده , , Alessia and Arcangeli، نويسنده , , Annarosa and Mini، نويسنده , , Enrico and Taddei، نويسنده , , Gianluigi، نويسنده ,
Abstract :
We studied the effects of luteinising hormone-releasing hormone (LHRH) agonist leuproreline (1 μM for 96 h) and LHRH antagonist cetrorelix on the cell growth of primary cultures from nine human endometrial cancers using the sulphorhodamine colorimetric test. Histological examinations and reverse transcription and polymerase chain reaction amplification (RT–PCR) for LHRH receptors were also performed. The endometrial cancers examined had a medium to high degree of proliferative activity and a low degree of apoptotic power; furthermore, they expressed the LHRH receptor RNA variably, detectable in 71% of cases. The addition of leuproreline or cetrorelix to cell cultures inhibited growth in a statistically significant way compared to untreated control cells; nevertheless, the percentage of cell growth inhibition obtained was very variable. These data suggest that LHRH analogues can exert differential inhibitory effects on the growth of endometrial cancer, which seems to be independent of the expression of specific LHRH receptors.
